Pekin Hardy Strauss’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$239K Sell
9,923
-2,392
-19% -$62.6K 0.02% 433
2026
Q1
$346K Sell
12,315
-1,315
-10% -$35K 0.04% 351
2025
Q4
$339K Buy
13,630
+2,921
+27% +$73.7K 0.03% 339
2025
Q3
$273K Sell
10,709
-1,350
-11% -$33.3K 0.03% 344
2025
Q2
$292K Buy
12,059
+1,880
+18% +$43.8K 0.03% 304
2025
Q1
$258K Sell
10,179
-11,716
-54% -$307K 0.03% 299
2024
Q4
$581K Sell
21,895
-6,000
-22% -$163K 0.07% 228
2024
Q3
$807K Buy
27,895
+800
+3% +$23.3K 0.1% 173
2024
Q2
$758K Buy
27,095
+2,090
+8% +$57.5K 0.1% 170
2024
Q1
$694K Sell
25,005
-1,161
-4% -$32.2K 0.09% 179
2023
Q4
$753K Sell
26,166
-37,458
-59% -$1.13M 0.11% 161
2023
Q3
$2.11M Sell
63,624
-3,570
-5% -$126K 0.33% 81
2023
Q2
$2.46M Sell
67,194
-2,633
-4% -$102K 0.27% 74
2023
Q1
$2.85M Sell
69,827
-2,569
-4% -$111K 0.38% 62
2022
Q4
$3.71M Sell
72,396
-1,958
-3% -$93.9K 0.51% 54
2022
Q3
$3.25M Buy
74,354
+39
+0.1% +$1.9K 0.52% 53
2022
Q2
$3.9M Buy
74,315
+1,500
+2% +$76.4K 0.55% 50
2022
Q1
$3.77M Sell
72,815
-700
-1% -$36.3K 0.47% 52
2021
Q4
$4.34M Buy
73,515
+1,000
+1% +$49.5K 0.59% 43
2021
Q3
$3.12M Buy
72,515
+1,093
+2% +$48.4K 0.45% 62
2021
Q2
$2.8M Buy
71,422
+1,625
+2% +$63.2K 0.39% 75
2021
Q1
$2.53M Buy
69,797
+3,785
+6% +$134K 0.4% 66
2020
Q4
$2.43M Sell
66,012
-1,994
-3% -$73.1K 0.42% 62
2020
Q3
$2.37M Buy
68,006
+4,637
+7% +$163K 0.48% 53
2020
Q2
$1.97M Sell
63,369
-513
-0.8% -$17.4K 0.43% 57
2020
Q1
$1.98M Sell
63,882
-2,045
-3% -$69.7K 0.44% 53
2019
Q4
$2.45M Sell
65,927
-184
-0.3% -$6.55K 0.4% 62
2019
Q3
$2.25M Sell
66,111
-8,632
-12% -$314K 0.44% 58
2019
Q2
$3.07M Sell
74,743
-295
-0.4% -$11.7K 0.61% 40
2019
Q1
$3.02M Sell
75,038
-211
-0.3% -$8.45K 0.24% 44
2018
Q4
$3.12M Buy
75,249
+14,430
+24% +$599K 0.54% 41
2018
Q3
$2.54M Sell
60,819
-2,767
-4% -$107K 0.44% 55
2018
Q2
$2.19M Sell
63,586
-6,867
-10% -$235K 0.42% 55
2018
Q1
$2.37M Sell
70,453
-395
-0.6% -$13.6K 0.43% 57
2017
Q4
$2.44M Sell
70,848
-5,187
-7% -$177K 0.44% 52
2017
Q3
$2.58M Sell
76,035
-9,951
-12% -$320K 0.48% 50
2017
Q2
$2.74M Sell
85,986
-2,664
-3% -$84K 0.43% 45
2017
Q1
$2.88M Sell
88,650
-1,702
-2% -$53.7K 0.56% 40
2016
Q4
$2.78M Buy
90,352
+2,472
+3% +$75.5K 0.25% 41
2016
Q3
$2.82M Buy
87,880
+1,133
+1% +$37.9K 0.48% 43
2016
Q2
$2.9M Sell
86,747
-4,545
-5% -$145K 0.64% 40
2016
Q1
$2.57M Sell
91,292
-8,393
-8% -$240K 0.6% 41
2015
Q4
$3.05M Buy
99,685
+3,024
+3% +$95.1K 0.69% 38
2015
Q3
$2.88M Sell
96,661
-1,772
-2% -$56.8K 0.66% 38
2015
Q2
$3.13M Buy
98,433
+61
+0.1% +$1.99K 0.61% 37
2015
Q1
$3.25M Buy
98,372
+42,916
+77% +$1.36M 0.6% 38
2014
Q4
$1.64M Sell
55,456
-485
-0.9% -$13.9K 0.24% 84
2014
Q3
$1.57M Buy
55,941
+8,295
+17% +$233K 0.27% 51
2014
Q2
$1.34M Buy
47,646
+22,545
+90% +$643K 0.21% 54
2014
Q1
$765K Buy
25,101
+3,188
+15% +$95.1K 0.12% 63
2013
Q4
$637K Sell
21,913
-764
-3% -$22.2K 0.1% 69
2013
Q3
$618K Buy
22,677
+306
+1% +$8.33K 0.1% 68
2013
Q2
$595K Buy
+22,371
New +$618K 0.1% 69

Other funds holding PFE

Pekin Hardy Strauss's PFE Position: Q2 2026 in Review

Pekin Hardy Strauss reduced its Pfizer (PFE) stake by 19% in Q2 2026, selling an estimated $62.6K and leaving 9,923 shares worth $239K. The position accounts for 0.02% of the portfolio, ranked #433.

Pekin Hardy Strauss first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.34M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Pekin Hardy Strauss held 9,923 shares of Pfizer worth $239K as of Q2 2026.
  • Pekin Hardy Strauss sold 2,392 Pfizer shares in Q2 2026, an estimated $62.6K.
  • Pfizer made up 0.02% of Pekin Hardy Strauss's portfolio in Q2 2026, its #433 holding.
  • Pekin Hardy Strauss first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Pekin Hardy Strauss's Pfizer position peaked at $4.34M in Q4 2021.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.